Figures S1-S11 from MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition

作者：Max Schlaak, Carolina Cimminiello, Jacopo Pigozzo, Jeeyun Lee, Stephan Grabbe, Piotr Rutkowski, Jacek Mackiewicz, Katy K. Tsai, Paolo A. Ascierto, Mario Mandalà, Fabrizio Carnevale‐Schianca, Sebastian Haferkamp, Victoria Atkinson, Jessica C. Hassel, Shahneen Sandhu, William H. Sharfman, Emma Dean, Urwah Noor, Sonia Iyer, Roy Rabbie, Antoni Ribas · 年份：2026 · DOI：10.1158/1078-0432.33014438 · 研究领域：Medicine、Oncology、Internal medicine、Pathology

<p>MONETTE study design, Baseline tumor sample and blood samples, DoR, best percentage change from baseline in target lesion size, OS in PD-L1 and CD8/Ki67 biomarker evaluable populations, micrographs of PD-L1 expression and CD8+/Ki67 cells, baseline area of CD8+ T cells, Ki67+ cells, and proliferating CD8+ Ki67 + T cells in the central tumor region, OS in the baseline circulating immune cell biomarker population, longitudinal pharmacodynamic effects on T cells, OS in GDF-15 biomarker population and baseline GDF-15 as a prognostic marker for OS in monotherapy and combination therapy.</p>